22 Jul 2021
CMR Surgical’s NHS footprint grows as Gloucestershire Royal Hospital adopts Versius
- Gloucestershire Royal Hospital has become the first NHS hospital to start with an upper GI programme with CMR Surgical’s next generation surgical robot, and will soon commence a multi-specialty programme including colorectal surgery
- For the first time the Trust’s upper GI patients are now benefiting from next-generation robotic technology with Versius
CMR Surgical (CMR) – a global surgical robotics business – today announced it has extended its NHS footprint as Gloucestershire Royal Hospital has become the latest hospital to adopt Versius. The programme has started with upper GI and will soon be a multi-specialty programme as surgeons across colorectal surgery are trained on the innovative system.
Gloucestershire Royal Hospital, part of Gloucestershire Hospitals NHS Foundation Trust which runs Gloucestershire Royal and Cheltenham General Hospitals, adopted Versius in order to build on its centre of excellence vision. Versius will support the hospital’s commitment to driving high quality care, allowing many more patients to benefit from minimally invasive surgery which results in less pain, shorter hospital stays and shorter recovery times than traditional open surgery.
The upper GI programme has already shown significant value for the hospital as surgeons were able to successfully perform the UK’s first nissen fundoplication – a laparoscopic procedure performed for patients with gastroesophageal reflux disease – as well as a hiatus hernia repair with Versius.
Simon Higgs, Consultant General and Upper GI Surgeon at Gloucestershire Royal Hospital, said:
“It was important for us to bring in Versius to the hospital so that patients having both routine surgeries like cholecystectomies as well as more complex procedures could benefit from the precision and accuracy that robotic surgery brings. Upper GI is an extremely busy department and adopting Versius signifies a new era for the specialty as many more patients will receive minimal access surgery and be treated with this high-quality technology.”
Mark Vipond, General Surgeon at Gloucestershire Royal Hospital, adds: “Versius brings multiple benefits for the Trust and we are delighted to be working with CMR Surgical on this programme. One of the key reasons Versius was so appealing to us was the small, modular design meaning that it can easily be transported to different departments so that it is being utilised as much as possible, bringing maximum value to the hospital and its patients. We’re looking forward to building on the fantastic start within upper GI and seeing additional specialties across the hospital benefit from the system.”
Versius is now established as a valuable surgical tool in a number of hospitals across Europe, India, Australia and the Middle East, where it is helping surgeons perform a wide range of procedures.
Mark Slack, Chief Medical Officer at CMR Surgical, said:
“It is great to be able to introduce Versius to the Gloucestershire Royal Hospital. In designing Versius our goal was to provide a versatile and cost-effective surgical robotic system that could transform the field of minimal access surgery – allowing more patients to benefit than currently do. This multi-specialty programme with Gloucestershire Royal will do exactly that and we’re delighted to be partnering with them on this exciting new era for the hospital.”
This announcement comes at an exciting time for CMR Surgical as it has recently announced it has raised $600 million (£425 million) in a Series D financing where the company will use the funds to bring Versius to more hospitals across the UK and existing markets, as well as entering new markets.